Sotera Health (NASDAQ:SHC) Receives $16.50 Average Price Target from Brokerages

Shares of Sotera Health (NASDAQ:SHC) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $16.50.

Several research firms recently commented on SHC. Citigroup lifted their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a report on Tuesday, August 6th. Finally, Barclays raised their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th.

Sotera Health Price Performance

Shares of NASDAQ SHC opened at $13.88 on Thursday. The company has a 50 day simple moving average of $15.88 and a two-hundred day simple moving average of $13.93. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The company has a market capitalization of $3.93 billion, a price-to-earnings ratio of 55.52 and a beta of 2.08. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. Analysts expect that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Activity at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 16.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 55.12% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SHC. William Blair Investment Management LLC lifted its stake in shares of Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock valued at $13,430,000 after buying an additional 6,707 shares in the last quarter. Clearline Capital LP purchased a new position in shares of Sotera Health in the second quarter valued at about $1,707,000. First Pacific Advisors LP purchased a new position in shares of Sotera Health in the second quarter valued at about $540,000. Darsana Capital Partners LP bought a new position in shares of Sotera Health in the second quarter worth about $29,074,000. Finally, Bank of New York Mellon Corp grew its position in shares of Sotera Health by 3.9% during the second quarter. Bank of New York Mellon Corp now owns 1,004,046 shares of the company’s stock worth $11,918,000 after purchasing an additional 37,681 shares in the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.